Tran Capital Management L.P. Has $35.99 Million Stock Position in Danaher Corporation $DHR

Key Points

• Tran Capital Management L.P. reduced its holdings in Danaher Corporation by 4.4%, owning 182,188 shares worth approximately $35.99 million at the end of the second quarter.
• Danaher recently reported quarterly earnings of $1.80 EPS, surpassing expectations, and generated revenues of $5.94 billion, up 3.4% year-over-year.
• The company announced a quarterly dividend of $0.32 per share, representing an annualized yield of 0.7%, to be paid on October 31st.

Tran Capital Management L.P. cut its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,188 shares of the conglomerate's stock after selling 8,331 shares during the period. Danaher comprises approximately 4.2% of Tran Capital Management L.P.'s portfolio, making the stock its 8th largest position. Tran Capital Management L.P.'s holdings in Danaher were worth $35,989,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Hills Bank & Trust Co boosted its position in Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after buying an additional 53 shares during the period. Sageworth Trust Co boosted its position in Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock worth $493,000 after buying an additional 54 shares during the period. 1834 Investment Advisors Co. boosted its position in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after buying an additional 54 shares during the period. Bruce G. Allen Investments LLC boosted its position in Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock worth $92,000 after buying an additional 54 shares during the period. Finally, Rakuten Securities Inc. boosted its position in Danaher by 33.3% during the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock worth $46,000 after buying an additional 56 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

DHR traded down $1.99 during trading on Tuesday, hitting $188.47. 1,592,017 shares of the company traded hands, compared to its average volume of 4,129,972. The firm has a market cap of $134.95 billion, a P/E ratio of 40.11, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75. The stock's fifty day moving average is $200.02 and its 200 day moving average is $198.03. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's dividend payout ratio is 27.23%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DHR. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. UBS Group dropped their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Evercore ISI dropped their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Bank of America dropped their price target on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $245.91.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.